Skip to content
Open access

Long Noncoding RNAs (lncRNAs) as Biomarkers of Prognosis in TNBC and Non-TNBC Breast Cancer Patients

Aug 2026 · International Journal of Molecular Sciences · Vol 27 · 0 citations · 66 references
Medicine

TL;DR

This computational study identifies several candidate lncRNAs associated with clinical outcomes in breast cancer, which should be interpreted as preliminary candidates, which require future validation and functional studies to determine their biological roles and evaluate their potential as prognostic biomarkers.

Abstract

Functional studies have shown that long noncoding RNAs (lncRNAs) play different roles in gene expression regulation, acting as epigenetic factors. Accumulating evidence indicates that lncRNAs modulate diverse biological processes, and their altered expression is associated with the development and progression of cancer, including BC. Here, aiming to identify lncRNAs associated with breast cancer, we performed a re-analysis of the expression data from 1071 tumors of eligible patients in the LACRN-MPBC Study. Using normalized data, we compared the expression profiles of triple-negative breast cancer (TNBC; 170 cases) and a heterogeneous group of non-TNBC tumors (782 cases). A total of 59 differentially expressed lncRNAs (DELncRNAs) could be identified based on the criteria of |log2FC| ≥ 1 and FDR < 0.05, using the DESeq2 R package. In the Kaplan–Meier survival analysis, we identified DELncRNAs that affect disease-free survival and/or overall survival, with eight of them in TNBC and 27 in non-TNBC patients. Multivariate Cox proportional-hazards models were used to evaluate independent predictors of survival. Two DELncRNAs, VLDLR-AS1 and PART1, were identified as independent prognostic markers for TNBC patients, while seven (LINC00239, FAM30A, LINC00842, LINC01315, EGOT, LY6E-DT, and SLC25A21-AS1) were independent prognostic markers for non-TNBC patients. Our computational study identifies several candidate lncRNAs associated with clinical outcomes in breast cancer. However, the DELncRNAs identified here should be interpreted as preliminary candidates, which require future validation and functional studies to determine their biological roles and evaluate their potential as prognostic biomarkers.

Read PDF

Similar papers

Aug 2026

Elevated Expression of LINC02257 and LINC00659 in Breast Cancer is Associated with Poor Survival and Immune Cell Infiltration

This study found that LINC02257 and LINC00659 are upregulated in BC and are associated with malignancy-related genes and patient survival, suggesting their potential as therapeutic targets and prognostic biomarkers.

Fatemeh Badzohre, Azin Azadfekr, Farnoosh Akbari et al. · 0 citations
Open access Jul 2026

Integrative multi-omics analysis identifies methylation-associated lncRNAs FAM83A-AS2 and AC012213.1 as candidate prognostic markers in lung adenocarcinoma

These findings nominate FAM83A-AS2 and AC012213.1 as candidate epigenetically associated prognostic lncRNAs in LUAD, warranting validation in independent cohorts and functional studies.

S. M. Al Sium, Mahafujul Islam Quadery Tonmoy, Dhirendra Nath Barman et al. · 0 citations
Open access Aug 2026

Anoikis associated long noncoding RNA signature predicts prognosis and small molecule drug response in glioma across multiple databases

The established eight-ARlncRNA signature serves as a robust prognostic tool, effectively predicting patient survival and mirroring the heterogeneity of the tumor immune landscape, and offers potential guidance for personalizing therapeutic strategies in glioma.

Yuting Ouyang, Rui Han, An-Qi Song et al. · 0 citations
Open access Jul 2026

Establishment and validation of RNA methylation-related lncRNAs signature that predicts prognosis and potential targeted therapy in hepatocellular carcinoma

A clinically applicable RNA methylation-related lncRNAs signature is developed that effectively predicts HCC prognosis and therapeutic response and provides valuable insights for risk stratification and may guide personalized treatment decisions in HCC management.

Yunchuan Yang, Xiang Ma, Chi Zhou et al. · 0 citations
Jul 2026

A prognostic immune signaling-related lncRNA-circRNA-mRNA network model for cervical cancer using machine learning.

This network modelling approach establishes that combinatorial modelling of coding and non-coding elements outperforms individual approaches, providing a robust framework for prognostic stratification and therapeutic targeting in cervical cancer.

V. B. Navya, Geethu Muraleedharan, P. K. Fasna et al. · 0 citations
Open access Jul 2026

LsGCRPred: lncRNA-SNP regulated gene expression based breast and ovarian cancer risk prediction model

This work put forward LSNP regulated gene expression based breast and ovarian cancer risk prediction model LsGCRPred (LSNP-Gene Interaction Based Cancer Risk Prediction Model), which accounts for the tissue-specificity of lncRNAs as well the benefit for individuals with predisposing conditions.

Troyee Das, Gourab Das, Byapti Ghosh et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.